Candidozyma auris, formerly Candida auris, is an emerging yeast that is now recognized as a major healthcare-associated pathogen worldwide. Its near-simultaneous emergence across multiple continents over the past decade, its high capacity to colonize skin, its prolonged environmental persistence, and its multidrug resistance to antifungal agents underscore its clinical and epidemiological significance. In Switzerland, the first case was documented in 2017. Since then, imported cases have been reported sporadically each year, almost exclusively among patients who were previously hospitalized in regions with high endemicity. This article presents the current epidemiological data and key issues related to infection prevention and control, and highlights the importance of implementing national recommendations.